Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 1.00 |
| ▸ | MMP2 | P08253 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 7/20 | 0.78 |
| ▸ | MAOB | P27338 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALPG | P10696 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705745 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL707946 | 0.88 | EGFR (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL707945 | 0.88 | EGFR (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL8065890 | 0.85 | MMP1 (0.73) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL8065891 | 0.85 | MMP1 (0.73) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL4205896 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL2682029 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| N-Phenylcinnamamide SCHEMBL3667414 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL1232872 | 0.83 | MAOB (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL9990629 | 0.83 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | MMP1 2401/4885MMP2 1766/4885MMP9 1210/4885 |
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | MMP1 3627/4885MMP2 1616/4885MMP9 1758/4885 |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MMP1 368/4885MMP2 853/4885MMP9 586/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MMP1 368/4885MMP2 853/4885MMP9 586/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | MMP1 752/4885MMP2 2166/4885MMP9 1065/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | MMP1 368/4885MMP2 853/4885MMP9 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.